Attr Amyloidosis clinical trials

Explore recruiting attr amyloidosis clinical trials.

Recruiting attr amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Attr Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Spain, Denmark, Netherlands, Belgium, Norway, Portugal +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of dapagliflozin on the quality of life and exercise capacity of patients with amyloid transthyretin cardiac amyloidosis: a pilot, phase 2b study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Denmark, Belgium, Italy, Sweden, Czechia, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis

Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

France, Germany, Italy, Greece, Belgium, Portugal +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).

Germany, France, Belgium, Italy, Denmark, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Attr Amyloidosis trials by city

Attr Amyloidosis in Toronto Attr Amyloidosis in Vancouver Attr Amyloidosis in Montreal Attr Amyloidosis in Calgary Attr Amyloidosis in Edmonton Attr Amyloidosis in Ottawa Attr Amyloidosis in Winnipeg Attr Amyloidosis in Quebec City Attr Amyloidosis in Hamilton Attr Amyloidosis in Kitchener Attr Amyloidosis in London Attr Amyloidosis in Halifax Attr Amyloidosis in New York Attr Amyloidosis in Los Angeles Attr Amyloidosis in Chicago Attr Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease